What happened
On September 7, 2026, Hualan Biological Vaccine Inc. announced it received a Drug Clinical Trial Approval Notice from China's National Medical Products Administration for its novel influenza virus mRNA vaccine, classified as a preventive biological product type 1.2.
The approval permits clinical trials to prevent influenza caused by vaccine-related virus strains. The company stated the vaccine uses mRNA technology to deliver antigens and induce immune responses, offering design flexibility and shorter production cycles.
As of the announcement date, no flu mRNA vaccine has been approved for market in China, making Hualan the first domestic company to receive implied permission for such a clinical trial. In contrast, Moderna's flu mRNA vaccine received FDA approval in August 2026.
Why it matters
This approval marks a significant step for mRNA vaccine technology in China, potentially paving the way for faster responses to influenza virus antigenic drift.
Being the first domestic player could give Hualan a competitive edge in the Chinese market, though the path to market remains long and uncertain.
Key facts
Hualan Vaccine received clinical trial approval for a novel influenza mRNA vaccine on September 7, 2026.
The vaccine is classified as a preventive biological product type 1.2.
No flu mRNA vaccine has been approved in China yet; Hualan is the first to get clinical trial permission.
Moderna's flu mRNA vaccine was approved by the U.S. FDA in August 2026.
What to watch next
The progress of Hualan's clinical trials and subsequent regulatory submissions.
Potential market entry of flu mRNA vaccines in China and competition from international players.